{{Drugbox
| Verifiedfields =
| verifiedrevid =
| IUPAC_name = 2-Phenyl-2-(methylamino)cyclohexanone
| image = Deschloroketamine.png
| width = 220
| image2 = Deschloroketamine3d.png

<!--Clinical data-->
| tradename =
| legal_status = Illegal in Latvia
| legal_CA = Schedule I
| legal_UK = Class B

<!--Identifiers-->
| CAS_number = 4631-27-0
| ATC_prefix =
| PubChem = 437168
| ChemSpiderID_Ref =
| ChemSpiderID = 386687

<!--Chemical data-->
| C=13 | H=17 | N=1 | O=1
| molecular_weight  =
| smiles = CNC1(CCCCC1=O)c2ccccc2
| StdInChI = 1S/C13H17NO/c1-14-13(10-6-5-9-12(13)15)11-7-3-2-4-8-11/h2-4,7-8,14H,5-6,9-10H2,1H3
| StdInChIKey = ZAGBSZSITDFFAF-UHFFFAOYSA-N
}}

'''Deschloroketamine''' ('''DXE, DCK, 2'-Oxo-PCM''') is a [[Dissociative drug|dissociative]] [[anesthesia|anesthetic]]<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0960894X10000648 | title=Synthesis and in vitro evaluation of <sup>18</sup>F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET |author1=Edward G. Robins |author2=Yongjun Zhao |author3=Imtiaz Khan |author4=Anthony Wilson |author5=Sajinder K. Luthra |author6=Erik Årstad | journal=Bioorganic & Medicinal Chemistry Letters | year=March 2010 | volume=20 | issue=5 | pages=1749–1751 | doi=10.1016/j.bmcl.2010.01.052 | pmid=20138515}}</ref><ref>{{cite web | url=http://www.google.com/patents/US3254124 | title=Patent US 3254124 - Aminoketones and methods for their production | date=31 May 1966 | accessdate=2 October 2015 | author=Calvin L Stevens}}</ref> that has been sold online as a [[designer drug]].<ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/rcm.7425/full | title=Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance |author1=Giampietro Frison |author2=Luca Zamengo |author3=Flavio Zancanaro |author4=Francesco Tisato |author5=Pietro Traldi | journal=Rapid Communications in Mass Spectrometry | date=January 2016 | volume=30 | issue=1 | pages=151–160 | doi=10.1002/rcm.7425 | pmid=26661982}}</ref><ref>{{cite web | url=http://energycontrol.org/analisis-de-sustancias/resultados/alertas/560-alerta-descloroketamina-vendida-como-ketamina-en-barcelona.html | title=Alerta: descloroketamina vendida como ketamina en Barcelona | publisher=Energy Control | language=Spanish | accessdate=2 October 2015}}</ref><ref>{{cite web | url=https://www.vice.com/es/read/los-efectos-desconocidos-de-la-sequia-de-ketamina-719 | title=Los efectos desconocidos de la sequía de ketamina | publisher=Vice | date=27 March 2015 | accessdate=2 October 2015 | author=Juanjo Villalba | language=Spanish}}</ref><ref>{{cite web | url=http://www.medicalrepublic.com.au/953-2/ | title=Party-drug testing shows its worth | publisher=The Medical Republic | date=22 October 2015 | author=Jeremy Knibbs}}</ref> It has also been proposed for the treatment of bacterial, fungal, viral or protozoal infections and for immunomodulation at doses of 2&nbsp;mg per day.<ref>{{cite web | url=http://www.google.com/patents/DE4409671C1 | title=Patent DE4409671 - Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial, fungal, viral or protozoal infections and for immunomodulation | date=23 May 1995 | accessdate=2 October 2015 |author1=Detlef Preiss |author2=Akos Tatar }}</ref>

==Legal Status==
Deschloroketamine is illegal in Latvia,<ref>[http://www.vm.gov.lv/images/userfiles/metodiskas_vadlinijas_080914.doc Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem]</ref> and is covered by blanket bans in Canada and the UK.

==References==
{{Reflist}}


{{Hallucinogens}}
{{Glutamate receptor modulators}}

[[Category:Designer drugs]]
[[Category:Dissociative drugs]]
[[Category:Ketones]]
[[Category:NMDA receptor antagonists]]


{{hallucinogen-stub}}